Trial Profile
Timing of Metabolic Response Monitoring During Erlotinib Treatment in Non–Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Dec 2015 New trial record